Form 4: TriSalus Life Sciences CEO Receives Stock Grant
SEC Form 4 Filing
Mary T. Szela, CEO and President of TriSalus Life Sciences, was granted 21,089 shares of common stock on February 18, 2025, which will vest on February 13, 2026, contingent upon continued service.
Summary
- Mary T. Szela, the CEO and President of TriSalus Life Sciences, received a grant of 21,089 shares of common stock on February 18, 2025.
- These shares are in the form of restricted stock units (RSU Award) and are payable solely in common stock of the Issuer.
- The shares will vest on February 13, 2026, provided that Ms. Szela continues to be employed by TriSalus Life Sciences on that date.
- Following this transaction, Ms. Szela beneficially owns 465,348 shares of TriSalus Life Sciences common stock.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. The sentiment is neutral to slightly positive.
Positives
- The grant of restricted stock units to the CEO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The vesting of the shares is contingent upon continued service, so there is a risk that the CEO may leave the company before the vesting date, which could disrupt the company's operations.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Stock grants are a common form of executive compensation in the life sciences industry, used to attract and retain talent and align management's interests with those of shareholders.
Stakeholder Impact
- Shareholders may view the stock grant positively as it incentivizes the CEO to increase shareholder value.
- Employees may view the stock grant positively as it indicates the company is investing in its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of transaction: Mary T. Szela received a grant of 21,089 shares of common stock. |
| 02/13/2026 | Vesting date for the restricted stock units, contingent upon continued service. |
| 02/19/2025 | Date of signature for the Form 4 filing. |
Keywords
TriSalus Life Sciences, Mary T. Szela, stock grant, restricted stock units, RSU, beneficial ownership, Form 4, TLSI, CEO, President
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.